Impact of atypical antipsychotics on outcomes of care in schizophrenia

American Journal of Managed Care

Volumn 11, Issue SUPPL. 8, 2005, Pages

  Joyce, Amie T ^a   Harrison, David J ^a   Loebel, Antony D ^a   Ollendorf, Daniel A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COST CONTROL; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 25444451093     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Regier DA, Narrow WE, Rae DS, et al. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85-94.
2. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003. 2003;54:508-516.
3. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ. 2000;321:1371-1376.
4. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002;24:21-37.
5. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
6. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136.
7. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002; 63:1121-1128.
8. Perkins DO. Adherence to antipsychotic medication. J Clin Psychiatry. 1999;60(suppl 21):25-30.
9. Al-Zakwani IS, Barron JJ, Bullano MF, et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin. 2003; 19:619-626.
10. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
11. Byerly MJ, Weber M, Brooks D, et al. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv. 2003;54:742-744.
12. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 2004;7:22-35.
13. Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics. 2003;21:683-697.
14. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 suppl):1-56.
15. Recommendations for atypical antipsychotic use in schizophrenia and schizoaffective disorders. Department of Veterans Affairs Pharmacy Benefits Management Strategic Healthcare Group, Medical Advisory Panel, and Mental Health Strategic Healthcare Group. Available at: http://www.vapbm.org. Accessed February 28, 2005.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
17. US Bureau of Labor Statistics. Available at: http://www.bls.gov/. Accessed June 20, 2005.
18. Bobes J, Canas F, Rejas J, et al. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1287-1297.
19. Whitehorn D, Richard JC, Kopala LC. Hospitalization in the first year of treatment for schizophrenia. Can J Psychiatry. 2004;49:635-638.
20. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.